Cargando…
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587/ https://www.ncbi.nlm.nih.gov/pubmed/30996573 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10 |
_version_ | 1783406302305714176 |
---|---|
author | Shi, Yuankai Han, Ying Yang, Jianliang Liu, Peng He, Xiaohui Zhang, Changgong Zhou, Shengyu Zhou, Liqiang Qin, Yan Song, Yongwen Liu, Yueping Wang, Shulian Jin, Jing Gui, Lin Sun, Yan |
author_facet | Shi, Yuankai Han, Ying Yang, Jianliang Liu, Peng He, Xiaohui Zhang, Changgong Zhou, Shengyu Zhou, Liqiang Qin, Yan Song, Yongwen Liu, Yueping Wang, Shulian Jin, Jing Gui, Lin Sun, Yan |
author_sort | Shi, Yuankai |
collection | PubMed |
description | OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site. RESULTS: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer’s ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer’s ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%. CONCLUSIONS: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis. |
format | Online Article Text |
id | pubmed-6433587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-64335872019-04-17 Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China Shi, Yuankai Han, Ying Yang, Jianliang Liu, Peng He, Xiaohui Zhang, Changgong Zhou, Shengyu Zhou, Liqiang Qin, Yan Song, Yongwen Liu, Yueping Wang, Shulian Jin, Jing Gui, Lin Sun, Yan Chin J Cancer Res Original Article OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site. RESULTS: In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer’s ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer’s ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%. CONCLUSIONS: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis. AME Publishing Company 2019-02 /pmc/articles/PMC6433587/ /pubmed/30996573 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10 Text en Copyright © 2019 Chinese Journal of Cancer Research. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Original Article Shi, Yuankai Han, Ying Yang, Jianliang Liu, Peng He, Xiaohui Zhang, Changgong Zhou, Shengyu Zhou, Liqiang Qin, Yan Song, Yongwen Liu, Yueping Wang, Shulian Jin, Jing Gui, Lin Sun, Yan Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title_full | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title_fullStr | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title_full_unstemmed | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title_short | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China |
title_sort | clinical features and outcomes of diffuse large b-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 who classified cases in a single institution in china |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587/ https://www.ncbi.nlm.nih.gov/pubmed/30996573 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10 |
work_keys_str_mv | AT shiyuankai clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT hanying clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT yangjianliang clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT liupeng clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT hexiaohui clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT zhangchanggong clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT zhoushengyu clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT zhouliqiang clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT qinyan clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT songyongwen clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT liuyueping clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT wangshulian clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT jinjing clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT guilin clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina AT sunyan clinicalfeaturesandoutcomesofdiffuselargebcelllymphomabasedonnodalorextranodalprimarysitesoforiginanalysisof1085whoclassifiedcasesinasingleinstitutioninchina |